A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group
- PMID: 1298221
- DOI: 10.1056/NEJM199209103271104
A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group
Abstract
Background: Valproate is approved for use primarily in patients with absence seizures, but the drug has a broad spectrum of activity against seizures of all types. Partial or secondarily generalized tonic-clonic seizures are often difficult to control adequately with standard treatment, usually carbamazepine or phenytoin.
Methods: We conducted a multicenter, double-blind trial that compared valproate with carbamazepine in the treatment of 480 adults with complex partial seizures (206 patients) or secondarily generalized tonic-clonic seizures (274 patients). The patients were randomly assigned to treatment with carbamazepine or divalproex sodium (valproate) at doses adjusted to achieve blood levels in the middle of the therapeutic range. Patients were followed for one to five years or until seizures became uncontrollable, treatment had unacceptable adverse effects, or both these events occurred.
Results: For the control of secondarily generalized tonic-clonic seizures, carbamazepine and valproate were comparably effective (in 136 patients and 138 patients, respectively). For complex partial seizures, four of five outcome measures favored carbamazepine (100 patients) over valproate (106 patients): the total number of seizures (2.7 vs. 7.6, P = 0.05), the number of seizures per month (0.9 vs. 2.2, P = 0.01), the time to the first seizure (P less than 0.02), and the seizure-rating score (P = 0.04). Carbamazepine was also superior according to a composite score that combined scores for the control of seizures and for adverse effects (P less than 0.001). Valproate was associated more frequently than carbamazepine with a weight gain of more than 5.5 kg (12 lb) (20 percent vs. 8 percent, P less than 0.001), with hair loss or change in texture (12 percent vs. 6 percent, P = 0.02), and with tremor (45 percent vs. 22 percent, P less than 0.001). Rash was more often associated with carbamazepine (11 percent vs. 1 percent, P less than 0.001).
Conclusions: Valproate is as effective as carbamazepine for the treatment of generalized tonic-clonic seizures, but carbamazepine provides better control of complex partial seizures and has fewer long-term adverse effects.
Comment in
-
Valproate versus carbamazepine for seizures.N Engl J Med. 1993 Jan 21;328(3):207-8; author reply 209. doi: 10.1056/NEJM199301213280310. N Engl J Med. 1993. PMID: 8417389 Clinical Trial. No abstract available.
-
Valproate versus carbamazepine for seizures.N Engl J Med. 1993 Jan 21;328(3):208. N Engl J Med. 1993. PMID: 8417390 No abstract available.
-
Valproate versus carbamazepine for seizures.N Engl J Med. 1993 Jan 21;328(3):208; author reply 209. N Engl J Med. 1993. PMID: 8417391 No abstract available.
-
Valproate versus carbamazepine for seizures.N Engl J Med. 1993 Jan 21;328(3):208-9. N Engl J Med. 1993. PMID: 8466565 No abstract available.
Similar articles
-
[Value of sodium valproate in the treatment of partial epilepsy].Praxis (Bern 1994). 1994 Oct 4;83(40):1140-3. Praxis (Bern 1994). 1994. PMID: 7939086 German.
-
Prolonged use of phenytoin, carbamazepine or valproate monotherapy on plasma levels of folate and B(12): a comparison between epileptic patients with or without cardiovascular disorders.Neuro Endocrinol Lett. 2006 Feb-Apr;27(1-2):85-8. Neuro Endocrinol Lett. 2006. PMID: 16648782
-
[Efficacy of sodium valproate in partial epilepsy. Crossed study of valproate and carbamazepine].Rev Neurol (Paris). 1984;140(6-7):434-7. Rev Neurol (Paris). 1984. PMID: 6431586 Clinical Trial. French.
-
Selection of drugs for the treatment of epilepsy.Semin Neurol. 1990 Dec;10(4):406-13. doi: 10.1055/s-2008-1063985. Semin Neurol. 1990. PMID: 2287835 Review.
-
Treatment of pediatric epilepsy: European expert opinion, 2007.Epileptic Disord. 2007 Dec;9(4):353-412. doi: 10.1684/epd.2007.0144. Epileptic Disord. 2007. PMID: 18077226 Review.
Cited by
-
Monitoring and antiepileptic drug safety.Continuum (Minneap Minn). 2013 Jun;19(3 Epilepsy):801-5. doi: 10.1212/01.CON.0000431392.31476.9e. Continuum (Minneap Minn). 2013. PMID: 23739112 Free PMC article. Review.
-
The natural history of epilepsy: an epidemiological view.J Neurol Neurosurg Psychiatry. 2004 Oct;75(10):1376-81. doi: 10.1136/jnnp.2004.045690. J Neurol Neurosurg Psychiatry. 2004. PMID: 15377680 Free PMC article. Review.
-
The effect of intracerebroventricular administration of orexin receptor type 2 antagonist on pentylenetetrazol-induced kindled seizures and anxiety in rats.BMC Neurosci. 2018 Aug 13;19(1):49. doi: 10.1186/s12868-018-0445-9. BMC Neurosci. 2018. PMID: 30103703 Free PMC article.
-
Management of focal-onset seizures: an update on drug treatment.Drugs. 2006;66(13):1701-25. doi: 10.2165/00003495-200666130-00004. Drugs. 2006. PMID: 16978035 Review.
-
BmK AEP, an Anti-Epileptic Peptide Distinctly Affects the Gating of Brain Subtypes of Voltage-Gated Sodium Channels.Int J Mol Sci. 2019 Feb 8;20(3):729. doi: 10.3390/ijms20030729. Int J Mol Sci. 2019. PMID: 30744067 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical